College of Medicine, University of Florida, Gainesville, Florida, USA.
Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA.
BMJ Case Rep. 2022 Nov 17;15(11):e251368. doi: 10.1136/bcr-2022-251368.
Patients with severe anaemia who refuse or cannot safely receive red cell transfusion present challenges during pregnancy, delivery and the postpartum period. Strategies including HBOC-201 (Hemopure) and intraoperative use of cell salvage have been used in non-pregnant patients to improve oxygen carrying capacity; however, these products pose unique risks in pregnant patients, those with sickle cell disease (SCD) and those undergoing caesarean section (C-section). We describe a case of a pregnant sickle beta+thalasasaemia patient who presented at 27 weeks gestation with pre-eclampsia and severe anaemia. As a Jehovah's Witness, she declined allogenic blood transfusion. The patient successfully underwent emergent C-section with cell salvage and received HBOC-201 immediately after delivery, during the operative procedure. To our knowledge, this is the first published report documenting a Jehovah's Witness patient with SCD who successfully received cell salvage and then HBOC-201 immediately postdelivery.
患有严重贫血且拒绝或不能安全接受红细胞输注的患者在妊娠、分娩和产褥期会带来挑战。在非妊娠患者中,已经使用了包括 HBOC-201(Hemopure)和术中使用细胞回收在内的策略来提高携氧能力;然而,这些产品在妊娠患者、镰状细胞病(SCD)患者和剖宫产(C -section)患者中存在独特的风险。我们描述了一例妊娠镰状β+地中海贫血患者的病例,她在 27 周妊娠时出现子痫前期和严重贫血。由于是耶和华见证人,她拒绝接受异体输血。患者成功地进行了紧急剖宫产和细胞回收,并且在手术过程中立即接受了 HBOC-201。据我们所知,这是首例记录有 SCD 的耶和华见证人患者成功接受细胞回收,然后在产后立即接受 HBOC-201 的报告。